Preliminary characterization of echinoderm assemblages in circalittoral and bathyal soft bottoms of the northern Alboran Sea

Echinoderms, with 7.272 species described so far (based on WORMS), provide an ecosystemic role which can be important depending on their habitat, and including tag species (Manjón-Cabeza et al., 2014; Palma-Sevilla 2015) or even dominant ones (Iken et al., 2010; Hughes et al., 2012). Despite the increasing knowledge on their taxonomy, studies on ecological and assemblage composition and structure of echinoderms are very scarce compared to those for other invertebrate groups, being this information essential for improving the knowledge on Mediterranean ecosystems (Coll et al., 2010). The Alboran Sea, in the junction of the Atlantic Ocean and the Mediterranean Sea and the European and African continental margins, represents a biodiversity hotspot due to the overlapping of species from those basins and continents, including some endemic components (Coll et al., 2010). Regarding echinoderms of the Alboran Sea, most previous studies focussed on infralittoral bottoms, with very few for circalittoral and bathyal ones (Manjón-Cabeza et al, 2014; Sibuet, 1974). Nevertheless, these studies generally included faunistic lists (Ocaña & Pérez-Ruzafa, 2004; Manjón-Cabeza et al., 2014), sometimes with identification keys, ecological and distributional data of some species and rarely on the assemblage composition and structure (Palma-Sevilla, 2015), which represent the main aim of this study on echinoderm assemblages of circalittoral and bathyal soft bottoms of the Alboran Sea. During the MEDITS survey expeditions (April-May 2014-2015) on board the R/V Miguel Oliver (Fig. 1), 35 samples were collected using a beam trawl (horizontal and vertical openings of 1.3 and 1.2 m, respectively, and a mesh size of 10 mm in the codend) at depths from 40 to 774 m in the Alboran Sea (Fig. 1). Hauls were done at a speed of ca. 2 knots during 5-10 (shelf stations) and 15 minutes (slope stations). Echinoderms were separated, identified to the lowest possible taxonomic leveland specimens counted and weighed to the nearest 0.5 g. Abundance and biomass data were standardized to 1000 m2 according to the sampling area of each haul. Echinoderm assemblages were characterized according to the dominance and frequency of occurrence of species in the samples and considering different ecological indexes. Multivariate methods (CLUSTER, nMDS, SIMPER, ANOSIM) were applied, based on the Bray & Curtis similarity index, for detecting and contrastingassemblages in relation to depth and 4 geographic areas of the Alboran Sea with different influence of Atlantic waters (Occidental-Esteponato Málaga, Central-Málaga to Motril, Oriental-Motril to Almería and Alboran Island). Fig. 1. Location of beam-trawl samples (dots) collected during 2014 and 2015 MEDITS expeditions in the northern Alboran Sea. At present 39 taxa have been detected, mostly belonging to Ophiuroidea and Asteroidea (28.2 and 25.6% of all species, respectively), followed by Holothuroidea (23.1%), Echinoidea (17.9%) and Crinoidea (5.1%). Regarding abundance, a total of 54689 individuals have been collected, being Ophiuroidea (98.6% of all individuals), Holothuroidea (0.6%) and Crinoidea (0.4%) the top-dominant classes. Regarding biomass, ophiuroids also dominated (52.8%), followed by asteroids (16.1%) and holothuroids (15.0%). Considering other faunistic groups, echinoderms were the most abundant phyllum in the samples (60.7%) and the fifth one in biomass (7.6%). The dominant (for both abundance and biomass) and frequent genera included Ophiocten (displaying dominances >90%) Hymenodiscus, Luidia and Astropecten for asteroids, Antedon and Leptometra for crinoids, Dendrochirotida and Molpadidae for holothuroids, and Brissopsis and Echinocyamus for echinoids (Fig. 2). Fig. 2. Some echinodermscollected in circalittoral and bathyal soft bottoms of the Alboran Sea using beam-trawl during the MEDITS expeditions. A: Ophiocten; B: Dendrochirotida sp.; C: Brissopsis; D: Anseropoda; E: Luidia. Multivariate analyses indicated groupings of samples and significantly different echinoderm assemblages in relation to depth (RANOSIM=0.22, p0.05). Shelf assemblages displayed lower intra-group similarities (<20% similarity in SIMPER) than the slope ones (ca. 40%). Species characterizing the shelf assemblages belonged to the genera Astropecten, Antedon, Ophiothrix among others, whereas those of the slope belonged to the genera Luidia (L. sarsi), Hymenodiscus, Ophiocten, Leptometra and Amphiura

Development of a small solar thermal power plant for heat and power supply to domestic and small business buildings

The small solar thermal power plant is being developed with funding from EU Horizon 2020 Program. The plant is configured around a 2-kWel Organic Rankine Cycle turbine and solar field, made of Fresnel mirrors. The solar field is used to heat thermal oil to the temperature of about 240°C. This thermal energy is used to run the Organic Rankine Cycle turbine and the heat rejected in its condenser (about 18-kWth) is utilised for hot water production and living space heating. The plant is equipped with a latent heat thermal storage to extend its operation by about 4 hours during the evening building occupancy period. The phase change material used is Solar salt with the melting/solidification point at about 220°C. The total mass of the PCM is about 3,800kg and the thermal storage capacity is about 100kWh. The operation of the plant is monitored by a central controller unit. The main components of the plant are being manufactured and laboratory tested with the aim to assemble the plant at the demonstration site, located in Catalonia, Spain. At the first stage of investigations the ORC turbine will be directly integrated with the solar field to evaluate their joint performance. During the second stage of tests, the Latent Heat Thermal Storage will be incorporated into the plant and its performance during the charging and discharging processes will be investigated. It is planned that the continuous field tests of the whole plant will be performed during the 2018-2019 period

Antioxidant therapies in traumatic brain injury: A review

Oxidative stress constitute one of the commonest mechanism of the secondary injury contributing to neuronal death in traumatic brain injury cases. The oxidative stress induced secondary injury blockade may be considered as to be a good alternative to improve the outcome of traumatic brain injury (TBI) treatment. Due to absence of definitive therapy of traumatic brain injury has forced researcher to utilize unconventional therapies and its roles investigated in the improvement of management and outcome in recent year. Antioxidant therapies are proven effective in many preclinical studies and encouraging results and the role of antioxidant mediaction may act as further advancement in the traumatic brain injury management it may represent aonr of newer moadlaity in neurosurgical aramamentorium, this kind of therapy could be a good alternative or adjuct to the previously established neuroprotection agents in TBI

Bladder cancer index: cross-cultural adaptation into Spanish and psychometric evaluation

BACKGROUND: The Bladder Cancer Index (BCI) is so far the only instrument applicable across all bladder cancer patients, independent of tumor infiltration or treatment applied. We developed a Spanish version of the BCI, and assessed its acceptability and metric properties. METHODS: For the adaptation into Spanish we used the forward and back-translation method, expert panels, and cognitive debriefing patient interviews. For the assessment of metric properties we used data from 197 bladder cancer patients from a multi-center prospective study. The Spanish BCI and the SF-36 Health Survey were self-administered before and 12 months after treatment. Reliability was estimated by Cronbach's alpha. Construct validity was assessed through the multi-trait multi-method matrix. The magnitude of change was quantified by effect sizes to assess responsiveness. RESULTS: Reliability coefficients ranged 0.75-0.97. The validity analysis confirmed moderate associations between the BCI function and bother subscales for urinary (r = 0.61) and bowel (r = 0.53) domains; conceptual independence among all BCI domains (r ≤ 0.3); and low correlation coefficients with the SF-36 scores, ranging 0.14-0.48. Among patients reporting global improvement at follow-up, pre-post treatment changes were statistically significant for the urinary domain and urinary bother subscale, with effect sizes of 0.38 and 0.53. CONCLUSIONS: The Spanish BCI is well accepted, reliable, valid, responsive, and similar in performance compared to the original instrument. These findings support its use, both in Spanish and international studies, as a valuable and comprehensive tool for assessing quality of life across a wide range of bladder cancer patients

Natural History of MYH7-Related Dilated Cardiomyopathy

BACKGROUND Variants in myosin heavy chain 7 (MYH7) are responsible for disease in 1% to 5% of patients with dilated cardiomyopathy (DCM); however, the clinical characteristics and natural history of MYH7-related DCM are poorly described. OBJECTIVES We sought to determine the phenotype and prognosis of MYH7-related DCM. We also evaluated the influence of variant location on phenotypic expression. METHODS We studied clinical data from 147 individuals with DCM-causing MYH7 variants (47.6% female; 35.6 +/- 19.2 years) recruited from 29 international centers. RESULTS At initial evaluation, 106 (72.1%) patients had DCM (left ventricular ejection fraction: 34.5% +/- 11.7%). Median follow-up was 4.5 years (IQR: 1.7-8.0 years), and 23.7% of carriers who were initially phenotype-negative developed DCM. Phenotypic expression by 40 and 60 years was 46% and 88%, respectively, with 18 patients (16%) first diagnosed at <18 years of age. Thirty-six percent of patients with DCM met imaging criteria for LV noncompaction. During follow-up, 28% showed left ventricular reverse remodeling. Incidence of adverse cardiac events among patients with DCM at 5 years was 11.6%, with 5 (4.6%) deaths caused by end-stage heart failure (ESHF) and 5 patients (4.6%) requiring heart transplantation. The major ventricular arrhythmia rate was low (1.0% and 2.1% at 5 years in patients with DCM and in those with LVEF of <= 35%, respectively). ESHF and major ventricular arrhythmia were significantly lower compared with LMNA-related DCM and similar to DCM caused by TTN truncating variants. CONCLUSIONS MYH7-related DCM is characterized by early age of onset, high phenotypic expression, low left ventricular reverse remodeling, and frequent progression to ESHF. Heart failure complications predominate over ventricular arrhythmias, which are rare. (C) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation

Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO2 study

The klotho and fibroblast growth factor 23 (FGF-23) pathway is implicated in cardiovascular pathophysiology. This substudy aimed to assess the changes in klotho and FGF-23 levels 1-month after dapagliflozin in patients with stable heart failure and reduced ejection fraction (HFrEF). The study included 29 patients (32.2% of the total), with 14 assigned to the placebo group and 15 to the dapagliflozin, as part of the double-blind, randomized clinical trial [DAPA-VO2 (NCT04197635)]. Blood samples were collected at baseline and after 30 days, and Klotho and FGF-23 levels were measured using ELISA Kits. Between-treatment changes (raw data) were analyzed by using the Mann-Whitney test and expressed as median (p25%–p75%). Linear regression models were utilized to analyze changes in the logarithm (log) of klotho and FGF-23. The median age was 68.3 years (60.8–72.1), with 79.3% male and 81.5% classified as NYHA II. The baseline medians of left ventricular ejection fraction, glomerular filtration rate, NT-proBNP, klotho, and FGF-23 were 35.8% (30.5–37.8), 67.4 ml/min/1.73 m2 (50.7–82.8), 1,285 pg/ml (898–2,305), 623.4 pg/ml (533.5–736.6), and 72.6 RU/ml (62.6–96.1), respectively. The baseline mean peak oxygen uptake was 13.1 ± 4.0 ml/kg/min. Compared to placebo, patients on dapagliflozin showed a significant median increase of klotho [Δ+29.5, (12.9–37.2); p = 0.009] and a non-significant decrease of FGF-23 [Δ−4.6, (−1.7 to −5.4); p = 0.051]. A significant increase in log-klotho (p = 0.011) and a decrease in log-FGF-23 (p = 0.040) were found in the inferential analysis. In conclusion, in patients with stable HFrEF, dapagliflozin led to a short-term increase in klotho and a decrease in FGF-23

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Background: Children with HIV-associated tuberculosis (TB) have few antiretroviral therapy (ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB. Methods: We nested a two-period, fixed-order pharmacokinetic substudy within the open-label, multicentre, randomised, controlled, non-inferiority ODYSSEY trial at research centres in South Africa, Uganda, and Zimbabwe. Children (aged 4 weeks to <18 years) with HIV-associated TB who were receiving rifampicin and twice-daily dolutegravir were eligible for inclusion. We did a 12-h pharmacokinetic profile on rifampicin and twice-daily dolutegravir and a 24-h profile on once-daily dolutegravir. Geometric mean ratios for trough plasma concentration (Ctrough), area under the plasma concentration time curve from 0 h to 24 h after dosing (AUC0–24 h), and maximum plasma concentration (Cmax) were used to compare dolutegravir concentrations between substudy days. We assessed rifampicin Cmax on the first substudy day. All children within ODYSSEY with HIV-associated TB who received rifampicin and twice-daily dolutegravir were included in the safety analysis. We described adverse events reported from starting twice-daily dolutegravir to 30 days after returning to once-daily dolutegravir. This trial is registered with ClinicalTrials.gov (NCT02259127), EudraCT (2014–002632-14), and the ISRCTN registry (ISRCTN91737921). Findings: Between Sept 20, 2016, and June 28, 2021, 37 children with HIV-associated TB (median age 11·9 years [range 0·4–17·6], 19 [51%] were female and 18 [49%] were male, 36 [97%] in Africa and one [3%] in Thailand) received rifampicin with twice-daily dolutegravir and were included in the safety analysis. 20 (54%) of 37 children enrolled in the pharmacokinetic substudy, 14 of whom contributed at least one evaluable pharmacokinetic curve for dolutegravir, including 12 who had within-participant comparisons. Geometric mean ratios for rifampicin and twice-daily dolutegravir versus once-daily dolutegravir were 1·51 (90% CI 1·08–2·11) for Ctrough, 1·23 (0·99–1·53) for AUC0–24 h, and 0·94 (0·76–1·16) for Cmax. Individual dolutegravir Ctrough concentrations were higher than the 90% effective concentration (ie, 0·32 mg/L) in all children receiving rifampicin and twice-daily dolutegravir. Of 18 children with evaluable rifampicin concentrations, 15 (83%) had a Cmax of less than the optimal target concentration of 8 mg/L. Rifampicin geometric mean Cmax was 5·1 mg/L (coefficient of variation 71%). During a median follow-up of 31 weeks (IQR 30–40), 15 grade 3 or higher adverse events occurred among 11 (30%) of 37 children, ten serious adverse events occurred among eight (22%) children, including two deaths (one tuberculosis-related death, one death due to traumatic injury); no adverse events, including deaths, were considered related to dolutegravir. Interpretation: Twice-daily dolutegravir was shown to be safe and sufficient to overcome the rifampicin enzyme-inducing effect in children, and could provide a practical ART option for children with HIV-associated TB